---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002323"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:02:55.681471+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iovance reaffirms FY2025 revenue guidance of $250-300M; cash $307M as of Q3

## Summary
- Expects to achieve previously disclosed FY2025 revenue guidance of $250-300M in first full year of Amtagvi sales.
- Cash position of $307M as of 9/30/25, expected to fund operations into Q2 2027.
- 85 authorized treatment centers as of 12/31/25; over 1,000 patients treated with commercial and clinical TIL products.
- Gross margin of 43% in Q3 2025; organization streamlined in Q3 2025 to support improved margins.
- IOV-LUN-202 NSCLC trial enrollment complete; data update expected in 2026 with potential launch in H2 2027.

## SEC filing metadata
- accession: 0001104659-26-002323
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465926002323/0001104659-26-002323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465926002323/tm262669d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002323
- JSON: https://secwatch.observer/filing/0001104659-26-002323.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.